Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Molecular Partners AG (MOLN.SW)
Schlieren, CH
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.14% | -2.90% | -6.23% | -11.73% | -11.47% | -11.21% | -10.42% | -49.83% | -85.53% | -88.85% | -86.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-3.8% Q1'26: +22.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +771.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.5% Q1'26: +1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q1'26: -0.06× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
26.63M
est: 27.68M (-3.8%)
|
29.12M
est: 26.45M (+10.1%)
|
23.04M
est: 24.20M (-4.8%)
|
20.02M
est: 12.32M (+62.5%)
|
10.36M
est: 46.95M (-77.9%)
|
20.38M
est: 30.37M (-32.9%)
|
9.34M
est: 28.66M (-67.4%)
|
9.33M
est: 15.43M (-39.5%)
|
189.56M
est: 184.72M (+2.6%)
|
7.04M
est: 7.86M (-10.5%)
|
4.97M
est: 4.47M (+11.3%)
|
—
est: 1.75M (-100.0%)
|
5.50M
5.46M – 5.54M
+214.3% YoY
|
30.75M
30.72M – 30.78M
+459.1% YoY
|
1.25M
1.25M – 1.25M
-95.9% YoY
|
33.55M
33.55M – 33.55M
+2,584.0% YoY
|
179.20M
179.20M – 179.20M
+434.1% YoY
|
| EBITDA |
-1.47M
est: -18.67M (+92.1%)
|
760.0K
est: 1.78M (-57.3%)
|
-17.52M
est: 2.18M (-902.1%)
|
-24.70M
est: -18.72M (-31.9%)
|
-36.11M
est: -38.37M (+5.9%)
|
-33.70M
est: -22.14M (-52.2%)
|
-59.58M
est: -79.10M (+24.7%)
|
-60.66M
est: -61.71M (+1.7%)
|
119.00M
est: -96.74M (+223.0%)
|
-59.52M
est: -2.16M (-2,658.3%)
|
-51.63M
est: -215.08M (+76.0%)
|
-53.26M
est: -480.3K (-10,988.4%)
|
-1.51M
-1.52M – -1.50M
-214.3% YoY
|
-8.44M
-8.45M – -8.43M
-459.1% YoY
|
-343.1K
-343.1K – -343.1K
+95.9% YoY
|
-9.21M
-9.21M – -9.21M
-2,584.0% YoY
|
-49.18M
-49.18M – -49.18M
-434.1% YoY
|
| EBIT |
-2.28M
est: -18.74M (+87.8%)
|
5.0K
est: 2.10M (-99.8%)
|
-18.61M
est: -1.71M (-986.7%)
|
-25.84M
est: -21.91M (-17.9%)
|
-37.04M
est: -41.55M (+10.9%)
|
-36.17M
est: -23.24M (-55.6%)
|
-62.47M
est: -86.97M (+28.2%)
|
-63.23M
est: -67.86M (+6.8%)
|
116.61M
est: -106.38M (+209.6%)
|
-61.95M
est: -2.18M (-2,745.0%)
|
-54.02M
est: -236.50M (+77.2%)
|
-55.44M
est: -484.7K (-11,337.4%)
|
-1.52M
-1.53M – -1.51M
-214.3% YoY
|
-8.52M
-8.52M – -8.51M
-459.1% YoY
|
-346.2K
-346.2K – -346.2K
+95.9% YoY
|
-9.29M
-9.29M – -9.29M
-2,584.0% YoY
|
-49.63M
-49.63M – -49.63M
-434.1% YoY
|
| Net Income |
-2.28M
est: -10.13M (+77.5%)
|
-148.8K
est: -2.60M (+94.3%)
|
-18.61M
est: -115.1K (-16,077.0%)
|
-25.43M
est: -20.93M (-21.5%)
|
-37.04M
est: -40.88M (+9.4%)
|
-36.29M
est: -23.01M (-57.7%)
|
-62.76M
est: -86.09M (+27.1%)
|
-63.79M
est: -67.17M (+5.0%)
|
117.85M
est: -105.30M (+211.9%)
|
-61.98M
est: -65.21M (+4.9%)
|
-54.04M
est: -64.80M (+16.6%)
|
-61.65M
est: -58.40M (-5.6%)
|
-54.70M
-65.18M – -30.35M
+6.3% YoY
|
-12.20M
-265.58M – 197.87M
+77.7% YoY
|
-55.14M
-59.42M – -45.43M
-352.1% YoY
|
-54.04M
-54.04M – -54.04M
+2.0% YoY
|
3.73M
3.73M – 3.73M
+106.9% YoY
|
| SGA |
4.90M
est: 51.27M (-90.4%)
|
6.22M
est: 19.89M (-68.7%)
|
7.24M
est: 4.81M (+50.4%)
|
8.28M
est: 8.14M (+1.7%)
|
9.46M
est: 13.31M (-28.9%)
|
13.16M
est: 5.88M (+123.9%)
|
11.03M
est: 53.08M (-79.2%)
|
16.91M
est: 28.57M (-40.8%)
|
21.82M
est: 38.20M (-42.9%)
|
19.00M
est: 14.28M (+33.0%)
|
17.16M
est: 8.11M (+111.6%)
|
13.47M
est: 3.18M (+323.8%)
|
9.99M
9.91M – 10.06M
+214.3% YoY
|
55.84M
55.79M – 55.89M
+459.1% YoY
|
2.27M
2.27M – 2.27M
-95.9% YoY
|
60.92M
60.92M – 60.92M
+2,584.0% YoY
|
325.41M
325.41M – 325.41M
+434.1% YoY
|
| EPS |
-0.15
est: -0.30 (+49.6%)
|
-0.01
est: -0.43 (+98.2%)
|
-0.91
est: -1.27 (+28.6%)
|
-1.22
est: -1.77 (+31.1%)
|
-1.75
est: -0.28 (-520.8%)
|
-1.69
est: -1.36 (-24.5%)
|
-2.51
est: -1.50 (-67.8%)
|
-2.06
est: -1.87 (-10.2%)
|
3.63
est: 3.50 (+3.7%)
|
-1.89
est: -1.75 (-8.0%)
|
-1.59
est: -1.77 (+10.4%)
|
-1.65
est: -1.57 (-5.3%)
|
-1.28
-1.75 – -0.81
+18.2% YoY
|
-0.91
-7.13 – 5.31
+29.1% YoY
|
-1.41
-1.59 – -1.22
-54.9% YoY
|
-1.45
-1.45 – -1.45
-3.1% YoY
|
0.10
0.10 – 0.10
+106.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.01% | 405.3K | 0.10% |
| 2 | Avantis International Equity ETF AVDE | 0.00% | 47.57 | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Patrick Amstutz | Co-Founder, Chief Executive Officer, Member of Management Board & Director | 657.0K | — |
| Daniel Steiner | Senior Vice President of Research & Technology | — | male |
| Laura Jeanbart | Head of Portfolio Management & Corporate Communications | — | female |
| Martin Steegmaier | Chief Scientific Officer & Member of the Management Board | — | male |
| Michael Pitzner | Executive VP of Partnering & General Counsel | — | male |
| Michael Tobias Stumpp | Co-Founder, Executive Vice President of Projects & Member of Management Board | — | — |
| Pamela A. Trail | Strategic Consultant | — | — |
| Philippe Legenne | Chief Medical Officer & Member of the Management Board | — | male |
| Renate Gloggner | Executive Vice President of People & Community and Member of Management Board | — | female |
| Robert Hendriks | Senior VP of Finance & Member of Management Board | — | male |
| Alexander Zurcher | Chief Operating Officer & Member of Management Board | — | male |
| Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MOLN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
